Women and Cancer
Women and Cancer
advertisement
top
bottom
Working Through It
Working Through It Cancer and Career

Many women diagnosed with cancer have questions about how their diagnosis and the treatment to come will affect their ability to work. The fact is, with the many supportive care treatments available today and with doctors and employers increasingly willing to work with patients to accommodate work and treatment schedules, many patients are able to continue to work through treatment.

Women&Cancer is inspired by the stories we have been able to share from women who have made their career and their cancer diagnosis work together. We know that each woman facing the question of how to balance a career and a cancer diagnosis has unique challenges related to her specific diagnosis and treatment plan, and that it’s not possible in all cases for women to continue to work. But we are dedicated to sharing stories and strategies to help women who feel they can work create a plan to balance their work and their treatment.

Articles
complimentary
Advice for Employees with Cancer
Work life doesn't stop once you have been diagnosed with cancer.
Latest Cancer News
Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Arimidex (03/09/2010)
Among postmenopausal women with early, hormone receptor-positive breast cancer treated with either tamoxifen (Nolvadex®) or Arimidex® (anastrozole), the Oncotype DX test predicts the risk of distant cancer recurrence in both node-negative and node-positive patients. These results were published in the Journal of Clinical Oncology.
Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer (03/09/2010)
Short-term hormone therapy delivered before and during moderate-dose radiation therapy improves survival and reduces risk of recurrence compared with radiation alone in men with intermediate-risk, early-stage prostate cancer. The results of this Phase III study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer (03/09/2010)
The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according to the results of a study presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
PCA3 Test May Help Guide Prostate Biopsy Decisions (03/08/2010)
The PCA3 urine test may help guide decisions about the need for repeat prostate biopsy in men with a negative initial biopsy but elevated PSA. These results were presented at the 2010 ASCO Genitourinary Cancer Symposium.
Cabazitaxel Shows Promise in Advanced Prostate Cancer (03/05/2010)
Among men with metastatic, hormone refractory prostate cancer that has progressed after Taxotere® (docetaxel)-based chemotherapy, the investigational chemotherapy drug cabazitaxel may improve survival. The results of this Phase III clinical trial will be presented at the ASCO 2010 Genitourinary Cancers Symposium.
More cancer news...
Subscribe
Women & Cancer is the premier women's health and wellness magazine, delivering breaking news about topics critical to women making informed decisions about their own and their family's health and emphasizing cancer prevention, early detection, management, and survivorship.